Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease
Event: ESC Congress 2024
Topic: Pharmacotherapy
Session: Clinical trial updates on the GLP-1 receptor agonist, semaglutide
